Skip to content

Study · Non-randomized trial · n = 10 · 1990

3 results

Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis.

Cattaneo M, Tenconi PM, Alberca I, Garcia VV, Mannucci PM

Thrombosis and haemostasis1 Nov 1990Cited by 25 (Europe PMC)

PMID2096487 (opens in a new tab)DOI10.1055/s-0038-1647318 (opens in a new tab)PepBankPUB-02096487
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with liver cirrhosis, desmopressin significantly shortened bleeding time one hour after injection.

    In plain wordsIn patients with liver cirrhosis, desmopressin significantly shortened bleeding time one hour after injection.

    Peptide
    Desmopressin
    Outcome
    DecreaseBleeding time one hour after injection
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.3 microgram/kg · subcutaneousAs given in this study (human).

    Measurements

    p
    < 0.05
    bleeding time one hour after injection

    Source sentences

    Summary
    One hour after DDAVP injection the bleeding time was significantly shortened (p less than 0.05).
    1 context sentence
    Summary · context
    We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 microgram/kg), a more practical route of administration than intravenous infusions.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with liver cirrhosis, bleeding time shortening after desmopressin was no longer statistically significant after 4 h.

    In plain wordsIn patients with liver cirrhosis, bleeding time shortening after desmopressin was no longer statistically significant after 4 h.

    Peptide
    Desmopressin
    Outcome
    No significant changeBleeding time four hours after injection
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.3 microgram/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After 4 h, however, the bleeding time shortening was no longer statistically significant.
    1 context sentence
    Summary · context
    We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 microgram/kg), a more practical route of administration than intravenous infusions.
  3. 03HumanNon-randomized trialMechanism

    In patients with liver cirrhosis, plasma vWF antigen did not significantly increase after desmopressin.

    In plain wordsIn patients with liver cirrhosis, a blood-clotting protein did not significantly increase after desmopressin.

    Peptide
    Desmopressin
    Outcome
    No significant changePlasma von Willebrand factor antigen
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.3 microgram/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Plasma levels of von Willebrand factor antigen (vWF:Ag) did not significantly increase after DDAVP or placebo.
    1 context sentence
    Summary · context
    We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 microgram/kg), a more practical route of administration than intravenous infusions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.